Autres langues NetraMark Holdings Inc. Canadian Securities Exchange

Actions

AIAI

CA64119M1059

Logiciels

Cours en clôture Canadian Securities Exchange Autres places de cotation 20/02/2026			Varia. 5j.	Varia. 1 janv.
1,070 ^CAD	-.--%		-3,77 %	-7,27 %

09/07	NetraMark bondit de 11 % après la signature d'un nouveau contrat d'analyse de données d'un essai de phase 2 sur la neurodégénérescence	MT
09/07	NetraMark Holdings Inc. signe un contrat d'analyse de données d'un essai de phase 2 sur la neurodégénérescence avec une organisation de recherche clinique partenaire	CI

Autres langues

13/07	NetraMark Engages AM Public Relations to Support Strategic Communications and Market Awareness
09/07	NetraMark Up 11% as It Signs a New Contract To Analyze Phase 2 Neurodegeneration Trial Data
09/07	NetraMark Holdings Inc. Signs Contract To Analyze Phase 2 Neurodegeneration Trial Data With Contract Research Organization Partner
09/07	NetraMark Signs New Contract To Analyze Phase 2 Neurodegeneration Trial Data With Contract Research Organization Partner
29/06	NetraMark to Perform AI-Assisted Analysis of Clinical Trial Data For Biopharm Company
29/06	NetraMark Holdings Inc. Signs NetraAI Clinical Trial Analysis Agreement with Late-Stage Biopharmaceutical Company
29/06	NetraMark Signs New NetraAI Clinical Trial Analysis Agreement with Late-Stage Biopharmaceutical Company
09/06	NetraMark Announces Presentation at Sidoti Small Cap Conference on June 18, 2026
25/05	Upcoming Meeting Dates - May 25, 2026
20/05	NetraMark to Present at the American Society of Clinical Psychopharmacology Annual Meeting
14/05	NetraMark Holdings Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2026
14/05	NetraMark Provides Second Quarter Update and Highlights Continued Commercial, Scientific, Regulatory and Capital Markets Momentum
07/05	NetraMark Announces Change To Board Of Directors
07/05	NetraMark Holdings Inc. Announces Resignation of Lawrence Guy as Director, Effective May 7, 2026
05/05	NetraMark Holdings Inc. (AIAI) Opens the Market
04/05	NetraMark Appoints Dr. Panteli Theocharous As Fractional Chief Medical Officer, Strengthening Clinical Leadership To Accelerate Global Adoption of NetraAI
04/05	NetraMark Holdings Inc. Announces Executive Changes
30/04	NetraMark To Open The Market At The Toronto Stock Exchange On May 5, 2026
22/04	NetraMark Positioned to Advance Psychedelic Clinical Trials Following U.S. Executive Order, Supported by Peer-Reviewed Research and Active Programs
22/04	NetraMark Holdings Inc. Positioned to Advance Psychedelic Clinical Trials Following U.S. Executive Order, Supported by Peer-Reviewed Research and Active Programs
20/04	Netramark Comments on U.S. Executive Order to Accelerate Treatments for Serious Mental Illness and Highlights the Need for Regulatory‑Grade Trial Design in Psychedelic Development
20/04	NetraMark Holdings Inc Announces NetraAI Platform For Clinical Trial Precision Analytics
09/04	Netramark Holdings Inc Announces Publication of Peer-Reviewed Article on Psychedelics and Quantum Brain Processes
09/04	Netramark-Authored, Peer-Reviewed Article Suggests Psychedelics Might Not Only Affect Brain Chemistry, They May Also Involve Quantum-Level Processes Inside the Brain
25/03	NetraMark Collaborating With Italian Company To Analyze Phase II Oncology Dataset